Join ASPHO's Industry Relations Council
Work with your target audience to advance pediatric hematology/oncology
As an organization that supports ASPHO’s mission and goals, your company is eligible to join ASPHO’s Industry Relations Council (IRC) to enjoy year-round benefits.
As an IRC member, you’ll gain:
- Expanded access to ASPHO leadership
- Ongoing visibility and recognition
- Exclusive discounts
- Opportunities to collaborate with ASPHO and its membership to improve patient care
Tiered participation ensures companies of all sizes benefit by joining ASPHO's IRC. Your company can join at the associate, executive, or premier level to take advantage of the benefits that best fit your needs, from newsletter advertising to 3-hour advisory board or focus group meetings.
Apply to join ASPHO's IRC today. For more information, contact This email address is being protected from spambots. You need JavaScript enabled to view it. .
Join These Companies on ASPHO's Industry Relations Council
Executive Level
bluebird bio
bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry.
With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. To learn more, visit https://www.bluebirdbio.com/.
For patients considering a bluebird bio gene therapy, there’s my bluebird support. my bluebird support is staffed by Patient Navigators who can provide resources, help answer questions, and assistance with next steps throughout the treatment journey. Available at no cost, enroll your patient online to start the conversation.
Servier
Servier is a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves. Governed by a non-profit foundation, Servier approaches innovation with a long-term vision, free of influence from investors and outside pressure to chase short-term monetary targets.
As a leader in oncology, Servier has significantly accelerated its investment in difficult and hard-to-treat cancers, with more than 50% of its research and development dedicated to delivering significant advances in areas of high unmet need throughout oncology with the potential to change the lives of the patients it serves. Within these areas, Servier is the leader in mutant IDH inhibition, with the first ever mutant IDH1 inhibitor approved in the U.S. and the European Union, and the company continues to drive the science behind targeted mutant IDH inhibition.
For other ways to support or partner with ASPHO, review our corporate support opportunities.